Avalyn Pharma, which is developing its AP01 pirfenidone inhalation solution for the treatment of idiopathic pulmonary fibrosis (IPF), has named Lyn Baranowski as CEO, succeeding Bruce Montgomery. Baranowski was most recently Chief Operating Officer of Altavant Sciences and has extensive experience in commercial and business roles at pharmaceutical companies, including Melinta Therapeutics, Pearl Therapeutics, Vatera Healthcare, and Novartis.
Baranowski commented, “Throughout my career, I have been driven by a passion to bring new respiratory medicines to patients with serious lung diseases who desperately need them. Avalyn’s portfolio of inhaled products impressed me with its potential to target important pulmonary medicines directly to the site of disease, sparing unnecessary systemic tissue exposure. I am looking forward to working with and building the Avalyn team to advance the company’s exciting clinical stage assets and build out our pipeline.”
Avalyn Chairman of the Board Niall O’Donnell said, “My colleagues and I would like to express our gratitude to Dr. Montgomery, who brought Avalyn’s lead programs successfully into clinical studies. Under his leadership, Avalyn built a strong scientific foundation, from which it will be well positioned to advance its business and clinical development objectives. We look forward to working with Ms. Baranowski, whose operational and strategic experience will be of vital importance as we enter this next phase of our evolution.”
Read the Avalyn Pharma press release.
